Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: T47D/TR-2 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: T47D/S2
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast carcinoma, tamoxifen-resistant
  • Disease: Cancer
  • Conditional: Yes
  • Application: T47D/TR-2 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells.
  • Description: The T47D/TR-2 Cell line is a breast cancer cell line resistant to tamoxifen. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details

  • Application: T47D/TR-2 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells.

Handling

  • Format: Frozen
  • Passage number: Passage 164 (AL3575, AL3576)
  • Growth medium: Phenol red free RPMI 1640 + 2% FCS + glutamax + 8Âľg Insulin/ml + 1 uM tamoxifen T47D/TR-2 are growth inhibited by fulvestrant.
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
  •   Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
  •   Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
  •   SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
  •   Thrane et al. 2014. Oncogene. :. PMID: 25362855.
  •   A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.